OSE Immunotherapeutics’ Board of Directors Proposes the Appointment of Eric Leire, MD, as New Independent Director
31 Maggio 2023 - 6:00PM
Business Wire
Ahead of the General Shareholders’ Meeting
of June 22, 2023
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo:
OSE) today announced that the Board of Directors, upon the
proposal of the Nomination and Remuneration Committee, has proposed
Eric Leire, MD, as an independent Director of the Company. This
appointment reflects the Company’s willingness to enlarge the
Board’s skills and expertise and to strengthen its international
scope to support its growth.
Moreover, the Board of Directors proposes the appointment of
Nicolas Poirier*, Chief Executive Officer of OSE
Immunotherapeutics, as director and of Anne-Laure Autret-Cornet,
Chief Financial Officer, as director representing the employee
shareholders who voted in her favor. The renewal of the term of
office of Pr. Brigitte Dréno and Pr. Gérard Tobelem as independent
directors is also proposed.
Eric Leire brings a professional international
experience, both in the US and in Europe, in biotechnology and in
the pharmaceutical industry. He is currently President and Chief
Executive Officer of Genflow Biosciences Ltd (listed on LSE:GENF /
gene therapy, senescence domain). Previously, he was Chairman and
President and Chief Executive Officer of two companies in the US:
Enochian Biosciences (listed on Nasdaq ENOB / cell and gene
therapy, VIH and cancer) and DanDrit Biotech (listed on OTCQB). He
formerly held the position of Marketing manager in the
pharmaceutical industry in the US and in Europe (Pfizer, Schering
Plough, Boots Pharma). Through his active experience in venture
capital funds in the health field at Medwell Capital (Canada) and
Biofund Venture (Denmark), he has developed biotech companies
financed by investment funds.
Eric Leire is a Medical Doctor (Grenoble University), holder of
a postgraduate diploma (DESS) in Health law (Sceaux University). He
spent 3 years as a researcher at the Harvard AIDS Institute. He
holds an MBA from HEC (ISA) and from Kellogg Graduate School of
Management (Chicago). Eric Leire is American and French
citizen.
* Nicolas Poirier, previously director representing the employee
shareholders, resigned with effect at the General Shareholders’
Meeting approving 2022 financial statements, further to his
appointment as Chief Executive Officer on October 7, 2022.
ABOUT OSE Immunotherapeutics OSE Immunotherapeutics is a
biotech company dedicated to developing first-in-class assets in
immuno-oncology and immuno-inflammation. The Company’s current
well-balanced first-in-class clinical pipeline includes:
- Tedopi® (immunotherapy activating tumor specific
T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is
the Company’s most advanced product; positive results from the
Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients
in secondary resistance after checkpoint inhibitor failure. Other
Phase 2 trials, sponsored by clinical oncology groups, of Tedopi®
in combination are ongoing in solid tumors.
- OSE-279 (anti-PD1): ongoing Phase 1/2 in solid tumors or
lymphomas (first patient included). OSE-279 is the backbone therapy
of the BiCKI® platform.
- OSE-127 - lusvertikimab (humanized monoclonal antibody
antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis
(sponsor OSE Immunotherapeutics); ongoing preclinical research in
leukemia (OSE Immunotherapeutics).
- FR-104/VEL-101 (anti-CD28 monoclonal antibody):
developed in partnership with Veloxis Pharmaceuticals, Inc. in
transplantation; ongoing Phase 1/2 in renal transplant (sponsor
Nantes University Hospital); Phase 1 ongoing in the US (sponsor
Veloxis Pharmaceuticals, Inc.).
- OSE-172/BI 765063 (anti-SIRPα monoclonal antibody on
CD47/SIRPα pathway) developed in partnership with Boehringer
Ingelheim in advanced solid tumors; positive Phase 1 dose
escalation results in monotherapy and in combination, in particular
with anti-PD-1 antibody ezabenlimab; international Phase 1b ongoing
clinical trial in combination with ezabenlimab alone or with other
drugs in patients with recurrent/metastatic head and neck squamous
cell carcinoma (HNSCC) and hepatocellular carcinoma (HCC).
OSE Immunotherapeutics expects to generate further significant
value from its two proprietary drug discovery platforms, which are
central to its ambitious goal to deliver next-generation
first-in-class immunotherapeutics:
- BiCKI® platform focused on immuno-oncology (IO) is a
bispecific fusion protein platform built on the key backbone
component of anti-PD1 combined with a new immunotherapy target to
increase anti-tumor efficacy. BiCKI-IL-7 is the most advanced
BiCKI® candidate targeting anti-PD1xIL-7.
- Myeloid platform focused on optimizing the therapeutic
potential of myeloid cells in IO and immuno-inflammation (I&I).
OSE-230 (ChemR23 agonist mAb) is the most advanced candidate
generated by the platform, with the potential to resolve chronic
inflammation by driving affected tissues to tissue integrity.
Additional information about OSE Immunotherapeutics assets is
available on the Company’s website: www.ose-immuno.com Click and
follow us on Twitter and LinkedIn
Forward-looking statements This press release contains
express or implied information and statements that might be deemed
forward-looking information and statements in respect of OSE
Immunotherapeutics. They do not constitute historical facts. These
information and statements include financial projections that are
based upon certain assumptions and assessments made by OSE
Immunotherapeutics’ management in light of its experience and its
perception of historical trends, current economic and industry
conditions, expected future developments and other factors they
believe to be appropriate. These forward-looking statements include
statements typically using conditional and containing verbs such as
“expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”,
their declensions and conjugations and words of similar import.
Although the OSE Immunotherapeutics management believes that the
forward-looking statements and information are reasonable, the OSE
Immunotherapeutics’ shareholders and other investors are cautioned
that the completion of such expectations is by nature subject to
various risks, known or not, and uncertainties which are difficult
to predict and generally beyond the control of OSE
Immunotherapeutics. These risks could cause actual results and
developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by
OSE Immunotherapeutics with the AMF. Such forward-looking
statements are not guarantees of future performance. This press
release includes only summary information and should be read with
the OSE Immunotherapeutics Universal Registration Document filed
with the AMF on May 2, 2023, including the annual financial report
for the fiscal year 2022, available on the OSE Immunotherapeutics’
website. Other than as required by applicable law, OSE
Immunotherapeutics issues this press release at the date hereof and
does not undertake any obligation to update or revise the
forward-looking information or statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230531005627/en/
OSE Immunotherapeutics Sylvie Détry
sylvie.detry@ose-immuno.com +33 1 53 198 757
Nicolas Poirier Chief Executive Officer
nicolas.poirier@ose-immuno.com +33 6 68 08 85 68
French Media: FP2COM Florence Portejoie
fportejoie@fp2com.fr +33 6 07 76 82 83
Grafico Azioni OSE Immunotherapeutics (EU:OSE)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni OSE Immunotherapeutics (EU:OSE)
Storico
Da Mag 2023 a Mag 2024